| 替格瑞洛、氯吡格雷对急性冠脉综合征患者PCI术后血小板聚集率、血流动力学及免疫功能的影响 |
| |
| 引用本文： | 王 珂,石继红,魏振衡.替格瑞洛、氯吡格雷对急性冠脉综合征患者PCI术后血小板聚集率、血流动力学及免疫功能的影响[J].天津医科大学学报,2020,0(1):35-38. |
| |
| 作者姓名： | 王 珂 石继红 魏振衡 |
| |
| 作者单位： | （周口市中心医院心内三科 ,周口466000） |
| |
| 摘 要： | 目的:探讨替格瑞洛、氯吡格雷对急性冠脉综合征（ACS）患者经皮冠状动脉介入治疗（PCI）术后血小板聚集率、血流动力学及免疫功能的影响。方法:选取本院心血管内科收治的124例ACS患者作为研究对象，随机分为观察组（n=62）和对照组（n =62），观察组给予替格瑞洛治疗，对照组给予氯吡格雷治疗，观察比较两组患者治疗前后小板聚集率、血流动力学指标、免疫功能指标变化情况和出血情况。结果:治疗后，两组患者血小板聚集率（PAV）均低于治疗前（P＜0.05），且观察组明显低于对照组（P＜0.05）；治疗后，两组患者全血黏度（BV）、血浆粘度（PV）均低于治疗前（P＜0.05），观察组明显低于对照组（P＜0.05），而收缩期血流速度峰值（SPV），舒张期血流速度峰值（DPV），冠脉血流储备（CFVR）均高于治疗前（P＜0.05），且观察组明显高于对照组（P＜0.05）；治疗后，两组患者CD3+、CD4+水平均高于治疗前（P＜0.05），观察组明显高于对照组（P＜0.05），而CD8+水平低于治疗前（P＜0.05），观察组低于对照组（P＜0.05）；两组患者总出血事件发生率比较差异无统计学意义（P＞0.05）。结论:替格瑞洛能有效抑制ACS患者PCI术后血小板凝集，改善血流动力学和免疫功能，安全性高。
|
| 关 键 词： | 急性冠脉综合征 替格瑞洛 氯吡格雷 血小板聚集率 血流动力学 免疫功能 |
The effects of Ticagrelor and Clopidogrel on platelet aggregation rate,hemodynamics and immunologic function in patients with acute coronary syndrome after PCI |
| |
| WANG Ke,SHI Ji-hong,WEI Zhen-heng.The effects of Ticagrelor and Clopidogrel on platelet aggregation rate,hemodynamics and immunologic function in patients with acute coronary syndrome after PCI[J].Journal of Tianjin Medical University,2020,0(1):35-38. |
| |
| Authors: | WANG Ke SHI Ji-hong WEI Zhen-heng |
| |
| Affiliation: | （Department of Heart 3 ，Zhoukou Central Hospital, Zhoukou 466000,China） |
| |
| Abstract: | Objective: To investigate the effects of Ticagrelor and Clopidogrel on platelet aggregation rate, hemodynamics and immunologic function in patients with acute coronary syndrome(ACS) after percutaneous coronary intervention(PCI). Methods:One hundred and twenty-four patients with ACS were randomly divided into observation group(n =62) and control group (n =62), the observation group was treated with Ticagrelor and the control group with Clopidogrel, and the platelet aggregation rate, hemodynamic index, immune function index and occurrence of Bleeding conditionwere observed and compared between the two groups before and after treatment. Results:After treatment, the platelet aggregation rate(PAV) of the two groups was lower than that before treatment (P＜0.05), and the observation group was significantly lower than the control group (P＜0.05); after treatment, the whole blood viscosity (BV) and plasma viscosity (PV) of the two groups were lower than those before treatment (P＜0.05), the observation group was significantly lower than the control group(P＜0.05), while the peak systolic velocity(SPV), peak diastolic velocity (DPV) and coronary flow velocityreserve(CFVR) were higher than those before treatment (P＜0.05),andthe observation group was significantly higher than the control group (P＜0.05); after treatment, the levels of CD3+ and CD4 + in the two groups were higher than those before treatment(P＜0.05), the level of CD8 + in the observation group was significantly higher than that in the control group (P＜0.05), and the levelof CD8+ in the observation group was lower than that before treatment (P＜0.05); there was no significant difference in the total incidence of bleeding events between the two groups(P＞0.05). Conclusion:Tigrelol can effectively inhibit platelet aggregation after PCI in ACS patients, and improve hemodynamics and immunologic function with high safety. |
| |
| Keywords: | acute coronary syndrome Ticagrelor Clopidogrel platelet aggregation rate hemodynamics immunologic function |
|
| 点击此处可从《天津医科大学学报》浏览原始摘要信息 |
|
点击此处可从《天津医科大学学报》下载全文 |
|
